Morgan Stanley Neogenomics Inc Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Neogenomics Inc stock. As of the latest transaction made, Morgan Stanley holds 2,488,487 shares of NEO stock, worth $26.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,488,487

Previous 1,546,259 60.94%

Holding current value

$26.4 Million

Previous $14.7 Million 23.97%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$6.4 - $10.27 $6.03 Million - $9.68 Million	942,228 Added 60.94%	2,488,487 $18.2 Million
Q1 2025 May 15, 2025	SELL	$9.09 - $18.61 $2.25 Million - $4.62 Million	-248,019 Reduced 13.82%	1,546,259 $14.7 Million
Q4 2024 Feb 14, 2025	SELL	$13.0 - $18.43 $1.78 Million - $2.52 Million	-136,771 Reduced 7.08%	1,794,278 $29.6 Million
Q3 2024 May 14, 2025	BUY	$13.4 - $17.73 $3.88 Million - $5.14 Million	289,688 Added 17.65%	1,931,049 $28.5 Million
Q3 2024 Nov 14, 2024	BUY	$13.4 - $17.73 $3.88 Million - $5.14 Million	289,688 Added 17.65%	1,931,049 $28.5 Million
Q2 2024 May 14, 2025	SELL	$13.01 - $15.77 $1.99 Million - $2.41 Million	-152,917 Reduced 8.52%	1,641,361 $22.8 Million
Q2 2024 Oct 17, 2024	SELL	$13.01 - $15.77 $2.24 Million - $2.71 Million	-171,847 Reduced 9.48%	1,641,361 $22.8 Million
Q2 2024 Aug 14, 2024	SELL	$13.01 - $15.77 $2.24 Million - $2.71 Million	-171,847 Reduced 9.48%	1,641,361 $22.8 Million
Q1 2024 Oct 17, 2024	BUY	$14.06 - $16.79 $2.42 Million - $2.89 Million	171,847 Added 10.47%	1,813,208 $28.5 Million
Q1 2024 Aug 16, 2024	SELL	$14.06 - $16.79 $2.13 Million - $2.54 Million	-151,358 Reduced 7.7%	1,813,208 $28.5 Million
Q1 2024 May 15, 2024	SELL	$14.06 - $16.79 $2.13 Million - $2.54 Million	-151,358 Reduced 7.7%	1,813,208 $28.5 Million
Q4 2023 Aug 16, 2024	BUY	$11.67 - $20.73 $3.77 Million - $6.7 Million	323,205 Added 19.69%	1,964,566 $31.8 Million
Q4 2023 Feb 13, 2024	SELL	$11.67 - $20.73 $360,392 - $640,183	-30,882 Reduced 1.55%	1,964,566 $31.8 Million
Q3 2023 Nov 15, 2023	SELL	$12.15 - $17.85 $1.81 Million - $2.66 Million	-148,867 Reduced 6.94%	1,995,448 $24.5 Million
Q2 2023 Aug 14, 2023	BUY	$14.1 - $19.83 $283,339 - $398,483	20,095 Added 0.95%	2,144,315 $34.5 Million
Q1 2023 May 15, 2023	BUY	$9.09 - $19.45 $2.76 Million - $5.9 Million	303,463 Added 16.67%	2,124,220 $37 Million
Q4 2022 Feb 14, 2023	BUY	$6.45 - $12.07 $1.78 Million - $3.33 Million	276,117 Added 17.88%	1,820,757 $16.8 Million
Q3 2022 Nov 14, 2022	BUY	$7.86 - $12.91 $1.78 Million - $2.93 Million	227,032 Added 17.23%	1,544,640 $13.3 Million
Q2 2022 Oct 27, 2022	BUY	$7.06 - $13.97 $3.61 Million - $7.14 Million	511,137 Added 63.38%	1,317,608 $10.7 Million
Q2 2022 Aug 15, 2022	BUY	$7.06 - $13.97 $3.61 Million - $7.14 Million	511,137 Added 63.38%	1,317,608 $10.7 Million
Q1 2022 Oct 27, 2022	SELL	$12.15 - $35.28 $6.21 Million - $18 Million	-511,137 Reduced 38.79%	806,471 $9.8 Million
Q1 2022 May 13, 2022	SELL	$12.15 - $35.28 $675,041 - $1.96 Million	-55,559 Reduced 6.45%	806,471 $9.8 Million
Q4 2021 Feb 14, 2022	SELL	$30.49 - $48.49 $2.72 Million - $4.33 Million	-89,267 Reduced 9.38%	862,030 $29.4 Million
Q3 2021 Nov 15, 2021	BUY	$41.66 - $52.52 $39.6 Million - $50 Million	951,297 New	951,297 $45.9 Million

Others Institutions Holding NEO

# of Institutions

307

Shares Held

129M

Call Options Held

1.17M

Put Options Held

297K

View Full List

About NEOGENOMICS INC

Ticker NEO
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 125,796,000
Market Cap $1.33B
Description
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...

More about NEO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account